The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
MetadataShow full item record
Meek, C., Lewis, H. B., Reimann, F., Gribble, F., & Park, A. J. (2015). The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides, 77 28-37. https://doi.org/10.1016/j.peptides.2015.08.013
Bariatric surgery for obesity has proved to be an extremely effective method of promoting long-term weight reduction with additional beneficial metabolic effects, such as improved glucose tolerance and remission of type 2 diabetes. A range of bariatric procedures are in common use, including gastric banding, sleeve gastrectomy and the Roux-en-Y gastric bypass. Although the mechanisms underlying the efficacy of bariatric surgery are unclear, gastrointestinal and pancreatic peptides are thought to play an important role. The aim of this review is to summarise the effects of different bariatric surgery procedures upon gastrointestinal and pancreatic peptides, including ghrelin, gastrin, cholecystokinin (CCK), glucose-dependent insulinotropic hormone (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), oxyntomodulin, insulin, glucagon and somatostatin.
Bariatric, Ghrelin, Gastrin, Cholecystokinin, Incretin, Oxyntomodulin
Research in the F. Reimann and F.M. Gribble laboratories is funded by the Wellcome Trust (WT084210Z/07/Z and WT088357Z/09/Z), the MRC (MRC_MC_UU_12012/3) and Full4Health (FP7/2011-2015, grant agreement no. 266408). Claire Meek receives additional salary funding from the Wellcome Trust Translational Medicine and Therapeutics Programme, funded by the Wellcome Trust in association with Glaxo SmithKline.
External DOI: https://doi.org/10.1016/j.peptides.2015.08.013
This record's URL: https://www.repository.cam.ac.uk/handle/1810/251213
Creative Commons Attribution 4.0
Licence URL: http://creativecommons.org/licenses/by/4.0/